Mylan N.V. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6,970
7,768
9,470
11,121
11,907
11,428
Cost of Goods Sold (COGS) incl. D&A
3,802
4,050
5,047
6,351
7,077
7,087
Gross Income
3,168
3,717
4,423
4,770
4,830
4,341
SG&A Expense
1,744
2,208
2,625
3,202
3,217
3,098
EBIT
1,424
1,510
1,797
1,568
1,613
1,243
Unusual Expense
183
127
365
1,058
136
309
Non Operating Income/Expense
167
9
74
158
5
23
Interest Expense
327
326
339
446
527
535
Pretax Income
747
975
915
122
903
298
Income Tax
121
41
68
358
207
54
Consolidated Net Income
627
933
848
480
696
353
Net Income
624
929
848
480
696
353
Net Income After Extraordinaries
624
929
848
480
696
353
Net Income Available to Common
624
929
848
480
696
353
EPS (Basic)
1.58
2.34
1.70
0.92
1.30
0.68
Basic Shares Outstanding
383
374
472
513
535
515
EPS (Diluted)
1.58
2.34
1.70
0.92
1.30
0.68
Diluted Shares Outstanding
394
398
497
521
537
517
EBITDA
1,922
2,049
2,798
3,091
3,419
3,353
Non-Operating Interest Income
-
-
-
12
6
-
Minority Interest Expense
-
3
4
-
-
-
Equity in Affiliates (Pretax)
-
91
105
113
58
79

About Mylan

View Profile
Address
Building 4
Hatfield Hertfordshire AL10 9UL
United Kingdom
Employees -
Website http://mylan.co.uk
Updated 07/08/2019
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other.